Urszula Tyrankiewicz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Urszula Tyrankiewicz has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Stefan Chlopicki
Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland
5 shared publications - Grzegorz Kwiatkowski
Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland
4 shared publications - Agnieszka Jasztal
Jagiellonian Centre for Experimental Therapeutics (JCET) Jagiellonian University Kraków Poland
2 shared publications - Agnieszka Kij
Jagiellonian University, Jagiellonian Centre for Experimental Therapeutics (JCET), Krakow, Poland
2 shared publications - Anna Kurpińska
Jagiellonian University, Jagiellonian Centre for Experimental Therapeutics (JCET), Krakow, Poland
2 shared publications - Izabela Czyzynska-Cichon
Jagiellonian University, Jagiellonian Centre for Experimental Therapeutics (JCET), Krakow, Poland
2 shared publications
Latest Publications
- Open Access
- 11 August 2026
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 122 (14) , 1992-2008
Liver sinusoidal endothelial cell defenestration in chronic heart failure is primarily dependent on cardiac diastolic dysfunction and is reversed by a sodium-glucose cotransporter 2 inhibitor but not by an angiotensin-converting enzyme inhibitor
Aims: Liver sinusoidal endothelial cells (LSECs) dysfunction was demonstrated to represent an early and persistent event in chronic heart failure (CHF), preceding congestive hepatopathy and contributing to the pathophysiology of the disease. However, it remains unknown whether classical CHF pharmacotherapy would reverse LSEC defenestration. Herein, we characterized the therapeutic effects of angiotensin-converting enzyme inhibitor (ACE-I)—perindopril—and sodium-glucose cotransporter 2 inhibitor (SGLT2-I)—empagliflozin—on the cardiohepatic axis and, in particular, on LSEC defenestration in the murine model of CHF. Methods and results: Untreated 6-month-old Tgαq*44 mice exhibited impaired systolic and diastolic cardiac function, impaired liver perfusion, and LSEC defenestration. Perindopril (2 mg/kg, 8 weeks of treatment, 4- to 6-month-old Tgαq*44 mice) significantly improved the left ventricular (LV) and right ventricular (RV) systolic function and ameliorated liver perfusion in vivo in Tgαq*44 mice. Perindopril also displayed a pronounced hepatoprotective effect, as evidenced by proteomic analysis of isolated hepatocytes, reduced total bilirubin, and gamma-glutamyltransferase; however, the number of LSEC fenestrations was unaffected in Tgαq*44 mice treated with perindopril. Empagliflozin (300 mg/kg, 8 weeks of treatment, 4- to 6-month-old Tgαq*44 mice) not only significantly improved LV and RV systolic function and ameliorated liver perfusion but also improved diastolic cardiac function and significantly reduced the defenestration of LSECs. Conclusion: LSEC defenestration was primarily driven by cardiac diastolic dysfunction, not by impaired liver perfusion or hepatocyte function, and was independent of biomarkers of congestive hepatopathy in the murine model of CHF in Tgαq*44 mice. As fully reversed by SGLT2-I, but not by ACE-I, LSEC defenestration emerges as a target in the treatment of the cardiohepatic axis in CHF, which is not uniformly improved by CHF pharmacotherapy.
- 11 August 2026
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 122 (14) , 1992-2008
Open AccessLiver sinusoidal endothelial cell defenestration in chronic heart failure is primarily dependent on cardiac diastolic dysfunction and is reversed by a sodium-glucose cotransporter 2 inhibitor but not by an angiotensin-converting enzyme inhibitor
Aims: Liver sinusoidal endothelial cells (LSECs) dysfunction was demonstrated to represent an early and persistent event in chronic heart failure (CHF), preceding congestive hepatopathy and contributing to the pathophysiology of the disease. However, it remains unknown whether classical CHF pharmacotherapy would reverse LSEC defenestration. Herein, we characterized the therapeutic effects of angiotensin-converting enzyme inhibitor (ACE-I)—perindopril—and sodium-glucose cotransporter 2 inhibitor (SGLT2-I)—empagliflozin—on the cardiohepatic axis and, in particular, on LSEC defenestration in the murine model of CHF. Methods and results: Untreated 6-month-old Tgαq*44 mice exhibited impaired systolic and diastolic cardiac function, impaired liver perfusion, and LSEC defenestration. Perindopril (2 mg/kg, 8 weeks of treatment, 4- to 6-month-old Tgαq*44 mice) significantly improved the left ventricular (LV) and right ventricular (RV) systolic function and ameliorated liver perfusion in vivo in Tgαq*44 mice. Perindopril also displayed a pronounced hepatoprotective effect, as evidenced by proteomic analysis of isolated hepatocytes, reduced total bilirubin, and gamma-glutamyltransferase; however, the number of LSEC fenestrations was unaffected in Tgαq*44 mice treated with perindopril. Empagliflozin (300 mg/kg, 8 weeks of treatment, 4- to 6-month-old Tgαq*44 mice) not only significantly improved LV and RV systolic function and ameliorated liver perfusion but also improved diastolic cardiac function and significantly reduced the defenestration of LSECs. Conclusion: LSEC defenestration was primarily driven by cardiac diastolic dysfunction, not by impaired liver perfusion or hepatocyte function, and was independent of biomarkers of congestive hepatopathy in the murine model of CHF in Tgαq*44 mice. As fully reversed by SGLT2-I, but not by ACE-I, LSEC defenestration emerges as a target in the treatment of the cardiohepatic axis in CHF, which is not uniformly improved by CHF pharmacotherapy.
- Open Access
- 3 March 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Defects in auxiliary fuel oxidation and mitochondrial pyruvate transport mark transition to overt heart failure in Tgαq*44 mice
Background: Defective catabolism of alternative and glucose-sparing fuel sources has recently been implicated in the development of cardiovascular and metabolic diseases, including heart failure (HF), but the molecular mechanisms and a causal relationship linking them to altered glucose metabolism are unknown. Methods: Herein, alterations in cardiac protein expression in an established HF model (Tgαq*44 mice) were explored at different ages (4−14 months) in relation to changes in energy substrate preference, high-energy phosphate metabolism, and a snapshot of plasma metabolites. A small cohort of HF cases ( n = 20) and non-failing controls ( n = 18) was also used to confirm translational value of the findings. Results: The progression of HF in Tgαq*44 mice was characterised by an increased reliance on glucose along with reduced mitochondrial oxidative metabolism that was associated with impaired MPC (mitochondrial pyruvate carrier)−mediated pyruvate utilisation and redirection of glycolytic intermediates into the hexose monophosphate shunt, glycogenesis, and serine biosynthetic pathway. Defects in fatty acid (FA), pyruvate, branched-chain amino acid (BCAA), and ketone body (KB) oxidation, alongside prominent elevation of lactate, represented major features of altered cardiac metabolism in end-stage HF. Chronic accumulation of BCAAs next to suppressed KB and disrupted glucose oxidation were also found in patients with advanced HF, underlying the clinical relevance of the observed alterations. Conclusion: This study provides the comprehensive pattern of metabolic evolution of HF, highlighting several possible avenues to rescue from the HF-prone phenotype, such as promoting BCAA and KB catabolism, or normalising glucose utilisation by overexpressing MPC.
- 3 March 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessDefects in auxiliary fuel oxidation and mitochondrial pyruvate transport mark transition to overt heart failure in Tgαq*44 mice
Background: Defective catabolism of alternative and glucose-sparing fuel sources has recently been implicated in the development of cardiovascular and metabolic diseases, including heart failure (HF), but the molecular mechanisms and a causal relationship linking them to altered glucose metabolism are unknown. Methods: Herein, alterations in cardiac protein expression in an established HF model (Tgαq*44 mice) were explored at different ages (4−14 months) in relation to changes in energy substrate preference, high-energy phosphate metabolism, and a snapshot of plasma metabolites. A small cohort of HF cases ( n = 20) and non-failing controls ( n = 18) was also used to confirm translational value of the findings. Results: The progression of HF in Tgαq*44 mice was characterised by an increased reliance on glucose along with reduced mitochondrial oxidative metabolism that was associated with impaired MPC (mitochondrial pyruvate carrier)−mediated pyruvate utilisation and redirection of glycolytic intermediates into the hexose monophosphate shunt, glycogenesis, and serine biosynthetic pathway. Defects in fatty acid (FA), pyruvate, branched-chain amino acid (BCAA), and ketone body (KB) oxidation, alongside prominent elevation of lactate, represented major features of altered cardiac metabolism in end-stage HF. Chronic accumulation of BCAAs next to suppressed KB and disrupted glucose oxidation were also found in patients with advanced HF, underlying the clinical relevance of the observed alterations. Conclusion: This study provides the comprehensive pattern of metabolic evolution of HF, highlighting several possible avenues to rescue from the HF-prone phenotype, such as promoting BCAA and KB catabolism, or normalising glucose utilisation by overexpressing MPC.
- Open Access
- 23 February 2024
- Published by Wiley in Acta Physiologica
- Vol. 240 (5) , e14114
Chronic heart failure induces early defenestration of liver sinusoidal endothelial cells (LSECs) in mice
Aim: Chronic heart failure (CHF) is often linked to liver malfunction and systemic endothelial dysfunction. However, whether cardio‐hepatic interactions in heart failure involve dysfunction of liver sinusoidal endothelial cells (LSECs) is not known. Here we characterize LSECs phenotype in early and end stages of chronic heart failure in a murine model.Methods: Right ventricle (RV) function, features of congestive hepatopathy, and the phenotype of primary LSECs were characterized in Tgαq*44 mice, with cardiomyocyte‐specific overexpression of the Gαq protein, at the age of 4‐ and 12‐month representative for early and end‐stage phases of CHF, respectively.Results: 4‐ and 12‐month‐old Tgαq*44 mice displayed progressive impairment of RV function and alterations in hepatic blood flow velocity resulting in hepatic congestion with elevated GGT and bilirubin plasma levels and decreased albumin concentration without gross liver pathology. LSECs isolated from 4‐ and 12‐month‐old Tgαq*44 mice displayed significant loss of fenestrae with impaired functional response to cytochalasin B, significant changes in proteome related to cytoskeleton remodeling, and altered vasoprotective function. However, LSECs barrier function and bioenergetics were largely preserved. In 4‐ and 12‐month‐old Tgαq*44 mice, LSECs defenestration was associated with prolonged postprandial hypertriglyceridemia and in 12‐month‐old Tgαq*44 mice with proteomic changes of hepatocytes indicative of altered lipid metabolism.Conclusion: Tgαq*44 mice displayed right‐sided HF and altered hepatic blood flow leading to LSECs dysfunction involving defenestration, shift in eicosanoid profile, and proteomic changes. LSECs dysfunction appears as an early and persistent event in CHF, preceding congestive hepatopathy and contributing to alterations in lipoprotein transport and CHF pathophysiology.
- 23 February 2024
- Published by Wiley in Acta Physiologica
- Vol. 240 (5) , e14114
Open AccessChronic heart failure induces early defenestration of liver sinusoidal endothelial cells (LSECs) in mice
Aim: Chronic heart failure (CHF) is often linked to liver malfunction and systemic endothelial dysfunction. However, whether cardio‐hepatic interactions in heart failure involve dysfunction of liver sinusoidal endothelial cells (LSECs) is not known. Here we characterize LSECs phenotype in early and end stages of chronic heart failure in a murine model.Methods: Right ventricle (RV) function, features of congestive hepatopathy, and the phenotype of primary LSECs were characterized in Tgαq*44 mice, with cardiomyocyte‐specific overexpression of the Gαq protein, at the age of 4‐ and 12‐month representative for early and end‐stage phases of CHF, respectively.Results: 4‐ and 12‐month‐old Tgαq*44 mice displayed progressive impairment of RV function and alterations in hepatic blood flow velocity resulting in hepatic congestion with elevated GGT and bilirubin plasma levels and decreased albumin concentration without gross liver pathology. LSECs isolated from 4‐ and 12‐month‐old Tgαq*44 mice displayed significant loss of fenestrae with impaired functional response to cytochalasin B, significant changes in proteome related to cytoskeleton remodeling, and altered vasoprotective function. However, LSECs barrier function and bioenergetics were largely preserved. In 4‐ and 12‐month‐old Tgαq*44 mice, LSECs defenestration was associated with prolonged postprandial hypertriglyceridemia and in 12‐month‐old Tgαq*44 mice with proteomic changes of hepatocytes indicative of altered lipid metabolism.Conclusion: Tgαq*44 mice displayed right‐sided HF and altered hepatic blood flow leading to LSECs dysfunction involving defenestration, shift in eicosanoid profile, and proteomic changes. LSECs dysfunction appears as an early and persistent event in CHF, preceding congestive hepatopathy and contributing to alterations in lipoprotein transport and CHF pathophysiology.
- Open Access
- 24 January 2023
- Published by Springer Nature in GeroScience
- Vol. 45 (3) , 1619-1648
Accelerated ageing and coronary microvascular dysfunction in chronic heart failure in Tgαq*44 mice
Age represents a major risk factor in heart failure (HF). However, the mechanisms linking ageing and HF are not clear. We aimed to identify the functional, morphological and transcriptomic changes that could be attributed to cardiac ageing in a model of slowly progressing HF in Tgαq*44 mice in reference to the cardiac ageing process in FVB mice. In FVB mice, ageing resulted in the impairment of diastolic cardiac function and in basal coronary flow (CF), perivascular and interstitial fibrosis without changes in the cardiac activity of angiotensin-converting enzyme (ACE) or aldosterone plasma concentration. In Tgαq*44 mice, HF progression was featured by the impairment of systolic and diastolic cardiac function and in basal CF that was associated with a distinct rearrangement of the capillary architecture, pronounced perivascular and interstitial fibrosis, progressive activation of cardiac ACE and systemic angiotensin-aldosterone-dependent pathways. Interestingly, cardiac ageing genes and processes were represented in Tgαq*44 mice not only in late but also in early phases of HF, as evidenced by cardiac transcriptome analysis. Thirty-four genes and 8 biological processes, identified as being ageing related, occurred early and persisted along HF progression in Tgαq*44 mice and were mostly associated with extracellular matrix remodelling and fibrosis compatible with perivascular fibrosis resulting in coronary microvascular dysfunction (CMD) in Tgαq*44 mice. In conclusion, accelerated and persistent cardiac ageing contributes to the pathophysiology of chronic HF in Tgαq*44 mice. In particular, prominent perivascular fibrosis of microcirculation resulting in CMD represents an accelerated cardiac ageing phenotype that requires targeted treatment in chronic HF.
- 24 January 2023
- Published by Springer Nature in GeroScience
- Vol. 45 (3) , 1619-1648
Open AccessAccelerated ageing and coronary microvascular dysfunction in chronic heart failure in Tgαq*44 mice
Age represents a major risk factor in heart failure (HF). However, the mechanisms linking ageing and HF are not clear. We aimed to identify the functional, morphological and transcriptomic changes that could be attributed to cardiac ageing in a model of slowly progressing HF in Tgαq*44 mice in reference to the cardiac ageing process in FVB mice. In FVB mice, ageing resulted in the impairment of diastolic cardiac function and in basal coronary flow (CF), perivascular and interstitial fibrosis without changes in the cardiac activity of angiotensin-converting enzyme (ACE) or aldosterone plasma concentration. In Tgαq*44 mice, HF progression was featured by the impairment of systolic and diastolic cardiac function and in basal CF that was associated with a distinct rearrangement of the capillary architecture, pronounced perivascular and interstitial fibrosis, progressive activation of cardiac ACE and systemic angiotensin-aldosterone-dependent pathways. Interestingly, cardiac ageing genes and processes were represented in Tgαq*44 mice not only in late but also in early phases of HF, as evidenced by cardiac transcriptome analysis. Thirty-four genes and 8 biological processes, identified as being ageing related, occurred early and persisted along HF progression in Tgαq*44 mice and were mostly associated with extracellular matrix remodelling and fibrosis compatible with perivascular fibrosis resulting in coronary microvascular dysfunction (CMD) in Tgαq*44 mice. In conclusion, accelerated and persistent cardiac ageing contributes to the pathophysiology of chronic HF in Tgαq*44 mice. In particular, prominent perivascular fibrosis of microcirculation resulting in CMD represents an accelerated cardiac ageing phenotype that requires targeted treatment in chronic HF.
- Open Access
- 19 July 2013
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 71 (7) , 730-737
The effect of the renin–angiotensin–aldosterone system inhibition on myocardial function in early and late phases of dilated cardiomyopathy in Tgaq*44 mice
The renin-angiotensin-aldosterone system (RAAS) determines progression of heart failure (HF) in humans, and RAAS inhibition is a major therapeutic strategy in HF. To assess the effect of angiotensin-converting enzyme inhibitor (ACE-I) and aldosterone receptor antagonist (ARA) therapy on the development of HF at its early and late stage in a murine model of dilated cardiomyopathy (Tgaq*44 mice). Tgaq*44 mice at the early or advanced stage of HF received combined therapy including ACE-I (perindopril 2 mg/kg) and ARA (canrenone 20 mg/kg). Cardiac function was assessed by magnetic resonance imaging before and after 2 months of treatment. Combined therapy with perindopril and canrenone resulted in preserved systolic function at the early stage and reduced chamber dilatation at the advanced stage of HF in Tgaq*44 mice. Activation of the RAAS is involved in progression of HF in Tgaq*44 mice with dilated cardiomyopathy. Therapeutic efficacy of ACE-I and ARA to inhibit systolic dysfunction and cardiac chamber dilation depends on the stage of HF development.
- 19 July 2013
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 71 (7) , 730-737
Open AccessThe effect of the renin–angiotensin–aldosterone system inhibition on myocardial function in early and late phases of dilated cardiomyopathy in Tgaq*44 mice
The renin-angiotensin-aldosterone system (RAAS) determines progression of heart failure (HF) in humans, and RAAS inhibition is a major therapeutic strategy in HF. To assess the effect of angiotensin-converting enzyme inhibitor (ACE-I) and aldosterone receptor antagonist (ARA) therapy on the development of HF at its early and late stage in a murine model of dilated cardiomyopathy (Tgaq*44 mice). Tgaq*44 mice at the early or advanced stage of HF received combined therapy including ACE-I (perindopril 2 mg/kg) and ARA (canrenone 20 mg/kg). Cardiac function was assessed by magnetic resonance imaging before and after 2 months of treatment. Combined therapy with perindopril and canrenone resulted in preserved systolic function at the early stage and reduced chamber dilatation at the advanced stage of HF in Tgaq*44 mice. Activation of the RAAS is involved in progression of HF in Tgaq*44 mice with dilated cardiomyopathy. Therapeutic efficacy of ACE-I and ARA to inhibit systolic dysfunction and cardiac chamber dilation depends on the stage of HF development.